Antibodies to the glutamate receptor in mania
Antibodies to the glutamate receptor in mania
复制标题
DOI：
10.1111/j.1399-5618.2012.01028.x
复制
发表时间：
2012-08-01
影响因子：
5.4
通讯作者：
Yolken, Robert
中科院分区：
文献类型：
--
作者：
Dickerson, Faith;Stallings, Cassie;Yolken, Robert
Dickerson F、Stallings C、Vaughan C、Origoni A、Khushalani S、Yolken R。躁狂症中谷氨酸受体的抗体。双相情感障碍 2012: 14: 547553。 (c) 2012 The Authors.Journal 汇编 (c) 2012 John Wiley & Sons A/S。背景：有证据表明谷氨酸能系统参与躁狂的病理生理学。 N-甲基-D-天冬氨酸 (NMDA) 受体 NR2 亚基的抗体已被证明会对谷氨酸功能产生不利影响。方法：我们测量了 60 名不同躁狂亚型患者（包括分裂情感病例）的 NMDA 受体 NR2 肽血清抗体，并在最多三个时间点进行了评估。我们还在其他精神病组的 295 名个体和 170 名非精神病对照者中测量了这些抗体。通过多变量分析比较组间的 NR2 抗体水平，并通过重复测量方差分析比较躁狂组内的 NR2 抗体水平。结果：在入院时（t = 2.99，p = 0.003）和评估时（t = 2.57，p = 0.010）测量时，与非精神病对照者相比，躁狂症患者的 NR2 肽抗体水平有所升高，但在六个月后的随访中则没有。其他精神病群体中个体的抗体水平与对照组人群中测量的水平没有显着差异。在躁狂症组中，在研究的三个时间点内抗体水平显着下降（F = 5.4，df = 2，p = 0.0067）。结论：NR2 抗体在躁狂急性期升高，但在随访期间不升高。我们的研究结果支持 NMDA 受体抗体在急性躁狂发病机制中的作用。
Dickerson F, Stallings C, Vaughan C, Origoni A, Khushalani S, Yolken R. Antibodies to the glutamate receptor in mania. Bipolar Disord 2012: 14: 547553. (c) 2012 The Authors.Journal compilation (c) 2012 John Wiley & Sons A/S. Background: There is evidence that the glutamatergic system is involved in the pathophysiology of mania. Antibodies to the NR2 subunits of the N-methyl-D-aspartate (NMDA) receptor have been shown to adversely affect glutamate functioning. Methods: We measured serum antibodies to the NR2 peptide of the NMDA receptor in 60 individuals with different subtypes of mania, including schizoaffective cases, who were assessed at up to three time points. We also measured these antibodies in 295 individuals in other psychiatric groups and in 170 non-psychiatric controls. NR2 antibody levels were compared among groups by multivariate analyses and within the mania group by repeated measures analysis of variance. Results: Individuals with mania had increased levels of antibodies to the NR2 peptide compared to levels in non-psychiatric controls when measured at the time of admission (t = 2.99, p = 0.003) and the time of evaluation (t = 2.57, p = 0.010), but not at follow-up six months later. The levels of antibodies in individuals in other psychiatric groups did not differ significantly from the levels measured in the control population. Within the mania group, there was a significant decrease in antibody levels over the three time points of the study (F = 5.4, df = 2, p = 0.0067). Conclusions: NR2 antibodies are elevated during the acute phase of mania but not at follow-up. Our findings support a role for antibodies to the NMDA receptor in the pathogenesis of acute mania.